124 related articles for article (PubMed ID: 16809183)
21. Killing time with enjoyment: a qualitative study of initiation into injecting drug use in north-east India.
Kermode M; Longleng V; Singh BC; Bowen K; Rintoul A
Subst Use Misuse; 2009; 44(8):1070-89. PubMed ID: 19544149
[TBL] [Abstract][Full Text] [Related]
22. Markers and risk factors for HCV, HBV and HIV in a network of injecting drug users in Melbourne, Australia.
Miller ER; Hellard ME; Bowden S; Bharadwaj M; Aitken CK
J Infect; 2009 May; 58(5):375-82. PubMed ID: 19328555
[TBL] [Abstract][Full Text] [Related]
23. Needle exchange use, sexual risk behaviour, and the prevalence of HIV, hepatitis B virus, and hepatitis C virus infections among Bulgarian injection drug users.
Vassilev ZP; Hagan H; Lyubenova A; Tomov N; Vasilev G; Krasteva D; Des Jarlais DC
Int J STD AIDS; 2006 Sep; 17(9):621-6. PubMed ID: 16942654
[TBL] [Abstract][Full Text] [Related]
24. Incidence of HIV, hepatitis C and hepatitis B viruses among injection drug users in southwestern China: a 3-year follow-up study.
Ruan Y; Qin G; Yin L; Chen K; Qian HZ; Hao C; Liang S; Zhu J; Xing H; Hong K; Shao Y
AIDS; 2007 Dec; 21 Suppl 8():S39-46. PubMed ID: 18172390
[TBL] [Abstract][Full Text] [Related]
25. Reducing HIV infection among new injecting drug users in the China-Vietnam Cross Border Project.
Des Jarlais DC; Kling R; Hammett TM; Ngu D; Liu W; Chen Y; Binh KT; Friedmann P
AIDS; 2007 Dec; 21 Suppl 8():S109-14. PubMed ID: 18172378
[TBL] [Abstract][Full Text] [Related]
26. Injecting drug users' experiences of targeted harm reduction in the Russian Federation.
Power R; Nozhkina N; Kanarsky I
Drug Alcohol Rev; 2005 Jan; 24(1):69-77. PubMed ID: 16191724
[No Abstract] [Full Text] [Related]
27. Drug injecting and syringe use in the HIV risk environment of Russian penitentiary institutions: Qualitative study.
Sarang A; Rhodes T; Platt L; Kirzhanova V; Shelkovnikova O; Volnov V; Blagovo D; Rylkov A
Addiction; 2006 Dec; 101(12):1787-96. PubMed ID: 17156178
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis C, B, and human immunodeficiency virus infections in illicit drug users in Israel: prevalence and risk factors.
Loebstein R; Mahagna R; Maor Y; Kurnik D; Elbaz E; Halkin H; Olchovsky D; Ezra D; Almog S
Isr Med Assoc J; 2008 Nov; 10(11):775-8. PubMed ID: 19070285
[TBL] [Abstract][Full Text] [Related]
29. The influence of needle exchange programs on injection risk behaviors and infection with hepatitis C virus among young injection drug users in select cities in the United States, 1994-2004.
Holtzman D; Barry V; Ouellet LJ; Des Jarlais DC; Vlahov D; Golub ET; Hudson SM; Garfein RS
Prev Med; 2009 Aug; 49(1):68-73. PubMed ID: 19410600
[TBL] [Abstract][Full Text] [Related]
30. HCV synthesis project: preliminary analyses of HCV prevalence in relation to age and duration of injection.
Hagan H; Des Jarlais DC; Stern R; Lelutiu-Weinberger C; Scheinmann R; Strauss S; Flom PL
Int J Drug Policy; 2007 Oct; 18(5):341-51. PubMed ID: 17854721
[TBL] [Abstract][Full Text] [Related]
31. Secondary syringe exchange as a model for HIV prevention programs in the Russian Federation.
Irwin K; Karchevsky E; Heimer R; Badrieva L
Subst Use Misuse; 2006; 41(6-7):979-99. PubMed ID: 16809182
[TBL] [Abstract][Full Text] [Related]
32. "I inject less as I have easier access to pipes": injecting, and sharing of crack-smoking materials, decline as safer crack-smoking resources are distributed.
Leonard L; DeRubeis E; Pelude L; Medd E; Birkett N; Seto J
Int J Drug Policy; 2008 Jun; 19(3):255-64. PubMed ID: 18502378
[TBL] [Abstract][Full Text] [Related]
33. Management of hepatitis C among drug users attending general practice in Ireland: baseline data from the Dublin area hepatitis C in general practice initiative.
Cullen W; Stanley J; Langton D; Kelly Y; Bury G
Eur J Gen Pract; 2007; 13(1):5-12. PubMed ID: 17366287
[TBL] [Abstract][Full Text] [Related]
34. 'There is no profile it is just everyone': the challenge of targeting hepatitis C education and prevention messages to the diversity of current and future injecting drug users.
Ellard J
Int J Drug Policy; 2007 May; 18(3):225-34. PubMed ID: 17689369
[TBL] [Abstract][Full Text] [Related]
35. Thinking ethically about needle and syringe programs.
Kleinig J
Subst Use Misuse; 2006; 41(6-7):815-25. PubMed ID: 16809168
[TBL] [Abstract][Full Text] [Related]
36. Hepatitis C virus incidence among young street-involved IDUs in relation to injection experience.
Roy E; Boudreau JF; Boivin JF
Drug Alcohol Depend; 2009 Jun; 102(1-3):158-61. PubMed ID: 19251382
[TBL] [Abstract][Full Text] [Related]
37. Respondent-driven sampling in a study of drug users in New York City: notes from the field.
McKnight C; Des Jarlais D; Bramson H; Tower L; Abdul-Quader AS; Nemeth C; Heckathorn D
J Urban Health; 2006 Nov; 83(6 Suppl):i54-9. PubMed ID: 16977493
[TBL] [Abstract][Full Text] [Related]
38. The organization of a community: community-based prevention of injecting drug use-related health problems.
Carruthers S
Subst Use Misuse; 2007; 42(12-13):1971-7. PubMed ID: 18075921
[TBL] [Abstract][Full Text] [Related]
39. Integrating multiple programme and policy approaches to hepatitis C prevention and care for injection drug users: a comprehensive approach.
Birkhead GS; Klein SJ; Candelas AR; O'Connell DA; Rothman JR; Feldman IS; Tsui DS; Cotroneo RA; Flanigan CA
Int J Drug Policy; 2007 Oct; 18(5):417-25. PubMed ID: 17854731
[TBL] [Abstract][Full Text] [Related]
40. Could the CARE-SHAKTI intervention for injecting drug users be maintaining the low HIV prevalence in Dhaka, Bangladesh?
Foss AM; Watts CH; Vickerman P; Azim T; Guinness L; Ahmed M; Rodericks A; Jana S
Addiction; 2007 Jan; 102(1):114-25. PubMed ID: 17207129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
